Dr. Beate Mueller-Tiemann, Chief Technology Officer at Cytiva, on her passion for leveraging technology to drive improved health outcomes.

The right automation design can meet your initial needs and be expanded for your future growth.

The efficacy of TIL therapies depends on how the original tumor samples are collected, harvested, and processed.